Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6695501 | 0.98 | ALDH1A1 (0.41) | ALDH1A1LMNAHSD17B10HTTGAA | |
| SCHEMBL19687864 | 0.85 | ALDH1A1 (0.34) | ALDH1A1HTTGAAMAPTPOLB | |
| SCHEMBL8986692 | 0.80 | TSHR (0.46) | ALDH1A1LMNAHSD17B10MAPTPOLB | |
| SCHEMBL27742724 | 0.79 | SLC18A3 (0.40) | ALDH1A1LMNAHSD17B10GAAMAPT | |
| SCHEMBL8990128 | 0.79 | TSHR (0.44) | ALDH1A1HTTGAACHRM1CHRM2 | |
| SCHEMBL65995 | 0.77 | SLC18A3 (0.53) | ALDH1A1CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL25166535 | 0.77 | TSHR (0.42) | ALDH1A1HTTGAAMAPTPOLB | |
| SCHEMBL9533341 | 0.77 | GAA (0.41) | ALDH1A1HTTGAAMAPTPOLB | |
| SCHEMBL21748712 | 0.76 | ALDH1A1 (0.46) | ALDH1A1LMNAHTTGAAMAPT | |
| SCHEMBL64545 | 0.76 | KMT2A (0.51) | ALDH1A1MAPTPOLBHPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2928882-B1 | PYRAZINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2017-01-18 | — | — | EP | disclosed |
| US-9512141-B2 | Pyrazine derivatives as CB2 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2016-12-06 | — | — | US | disclosed |
| CN-105916500-A | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases | 欧洲筛选有限公司 | 2016-08-31 | — | — | CN | disclosed |
| US-20150299220-A1 | NOVEL PYRAZINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2928882-A1 | NOVEL PYRAZINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2015-10-14 | — | — | EP | disclosed |
| CN-102812003-B | Pyrrolidine Or Thiazolidine Carboxylic Acid Derivatives, Pharmaceutical Composition And Methods For Use In Treating Metabolic Disordersas As Agonists Of G- Protein Coupled Receptor 43 (GPR43) | EUROSCREEN SA | 2015-01-21 | — | — | CN | disclosed |
| WO-2014086807-A1 | NOVEL PYRAZINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
| CN-102812003-A | Pyrrolidine Or Thiazolidine Carboxylic Acid Derivatives, Pharmaceutical Composition And Methods For Use In Treating Metabolic Disordersas As Agonists Of G- Protein Coupled Receptor 43 (GPR43) | EUROSCREEN SA | 2012-12-05 | — | — | CN | disclosed |
| EP-1885375-A1 | NOVEL NSAIDS POSSESSING A NITRIC OXIDE DONOR DIAZEN-1-IUM-1,2-DIOLATE MOIETY | The Governors of the University of Alberta (CA) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006125016-A1 | NOVEL NSAIDS POSSESSING A NITRIC OXIDE DONOR DIAZEN-1-IUM-1,2-DIOLATE MOIETY | THE GOVERNORS OF THE UNIVERISITY OF ALBERTA (CA) | 2006-11-23 | — | — | WO | disclosed |
| EP-1539783-A1 | INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004018496-A1 | INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299220-A1 | NOVEL PYRAZINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | CNR1, CNR2, GPR55 | ALDH1A1 3377/4885LMNA 3369/4885HSD17B10 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.